The addition of vericiguat to sacubitril/valsartan improved the composite endpoint. Add a finishing touch on heart failure medical therapy by vericiguat as secret ingredient.

Eur J Heart Fail · 2025 · PMC12803529 · PMID 41065539

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

showed a trendp = 0.01actually significant

However, the add vericiguat group showed a trend toward a significantly lower risk of the composite endpoint compared to the sacubitril/valsartan group (HR 0.34, 95% CI 0.12–0.82, p = 0.01).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.